Two Sigma Advisers
RIGL icon

Two Sigma Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History

Two Sigma Advisers’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,198
Closed -$694K – 1693
2025
Q4 		$694K Buy
16,198
+7,870
+95% +$297K ﹤0.01% 1660
2025
Q3 		$236K Sell
8,328
-22,789
-73% -$682K ﹤0.01% 2073
2025
Q2 		$583K Sell
31,117
-10,811
-26% -$205K ﹤0.01% 1682
2025
Q1 		$754K Sell
41,928
-21,200
-34% -$430K ﹤0.01% 1599
2024
Q4 		$1.06M Buy
63,128
+24,400
+63% +$468K ﹤0.01% 1428
2024
Q3 		$627K Buy
38,728
+4,399
+13% +$51.7K ﹤0.01% 1612
2024
Q2 		$282K Sell
34,329
-27,990
-45% -$293K ﹤0.01% 2094
2024
Q1 		$922K Sell
62,319
-3,541
-5% -$47.7K ﹤0.01% 1620
2023
Q4 		$955K Sell
65,860
-37,269
-36% -$381K ﹤0.01% 1666
2023
Q3 		$1.11M Sell
103,129
-116,440
-53% -$1.4M ﹤0.01% 1473
2023
Q2 		$2.83M Sell
219,569
-17,100
-7% -$231K 0.01% 1022
2023
Q1 		$3.12M Buy
236,669
+56,770
+32% +$902K 0.01% 1029
2022
Q4 		$2.7M Sell
179,899
-14,930
-8% -$137K 0.01% 1074
2022
Q3 		$2.3M Buy
194,829
+163,270
+517% +$2.21M 0.01% 1100
2022
Q2 		$357K Buy
31,559
+26,380
+509% +$530K ﹤0.01% 2066
2022
Q1 		$155K Sell
5,179
-51,480
-91% -$1.39M ﹤0.01% 2425
2021
Q4 		$1.5M Sell
56,659
-124,810
-69% -$3.77M ﹤0.01% 1331
2021
Q3 		$6.59M Sell
181,469
-9,500
-5% -$374K 0.02% 667
2021
Q2 		$8.29M Sell
190,969
-45,980
-19% -$1.74M 0.02% 641
2021
Q1 		$8.1M Buy
236,949
+201,000
+559% +$7.96M 0.02% 653
2020
Q4 		$1.26M Sell
35,949
-67,550
-65% -$1.96M ﹤0.01% 1465
2020
Q3 		$2.48M Buy
103,499
+17,910
+21% +$440K 0.01% 1052
2020
Q2 		$1.57M Buy
85,589
+4,720
+6% +$84.9K ﹤0.01% 1344
2020
Q1 		$1.26M Buy
80,869
+2,220
+3% +$47.3K ﹤0.01% 1354
2019
Q4 		$1.68M Buy
78,649
+11,830
+18% +$244K ﹤0.01% 1309
2019
Q3 		$1.25M Buy
66,819
+10,580
+19% +$219K ﹤0.01% 1336
2019
Q2 		$1.47M Buy
56,239
+5,000
+10% +$113K ﹤0.01% 1341
2019
Q1 		$1.32M Buy
51,239
+33,940
+196% +$776K ﹤0.01% 1401
2018
Q4 		$398K Sell
17,299
-3,600
-17% -$102K ﹤0.01% 1860
2018
Q3 		$671K Buy
20,899
+5,090
+32% +$153K ﹤0.01% 1678
2018
Q2 		$447K Buy
15,809
+1,090
+7% +$38.8K ﹤0.01% 1962
2018
Q1 		$521K Buy
14,719
+4,440
+43% +$178K ﹤0.01% 1800
2017
Q4 		$399K Buy
10,279
+2,400
+30% +$91.3K ﹤0.01% 1849
2017
Q3 		$200K Sell
7,879
-1,460
-16% -$35.5K ﹤0.01% 2055
2017
Q2 		$255K Sell
9,339
-830
-8% -$22.7K ﹤0.01% 2044
2017
Q1 		$337K Sell
10,169
-9,750
-49% -$248K ﹤0.01% 2051
2016
Q4 		$474K Sell
19,919
-7,390
-27% -$212K ﹤0.01% 1895
2016
Q3 		$1M Buy
27,309
+3,120
+13% +$89.4K ﹤0.01% 1356
2016
Q2 		$539K Sell
24,189
-3,930
-14% -$97.7K ﹤0.01% 1480
2016
Q1 		$585K Sell
28,119
-510
-2% -$12.6K ﹤0.01% 1399
2015
Q4 		$867K Sell
28,629
-2,820
-9% -$85.5K 0.01% 1093
2015
Q3 		$790K Sell
31,449
-3,250
-9% -$97K 0.01% 1115
2015
Q2 		$1.11M Buy
34,699
+6,220
+22% +$238K 0.01% 1078
2015
Q1 		$1.02M Buy
28,479
+2,730
+11% +$74.9K 0.01% 1065
2014
Q4 		$585K Buy
25,749
+2,850
+12% +$57.6K ﹤0.01% 1503
2014
Q3 		$444K Sell
22,899
-1,020
-4% -$28.8K ﹤0.01% 1618
2014
Q2 		$868K Buy
23,919
+1,650
+7% +$56.1K 0.01% 1274
2014
Q1 		$863K Sell
22,269
-1,350
-6% -$48.1K 0.01% 1243
2013
Q4 		$672K Buy
+23,619
New +$693K 0.01% 1399

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers's RIGL Position: Q1 2026 in Review

Two Sigma Advisers sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 16,198 shares — an estimated $694K sold.

Two Sigma Advisers first reported a position in RIGL in Q4 2013 and held it in 49 quarters. The position peaked at $8.29M in Q2 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Two Sigma Advisers reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 16,198 Rigel Pharmaceuticals shares in Q1 2026, an estimated $694K.
  • Two Sigma Advisers first reported a position in Rigel Pharmaceuticals in Q4 2013 and held it in 49 quarters.
  • Two Sigma Advisers's Rigel Pharmaceuticals position peaked at $8.29M in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.